-

Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden

The state-of-the-art facility enhances support for complex modalities across all phases of drug development

Key facts

  • Thermo Fisher opens new bioanalytical and biomarker laboratory in Gothenburg, Sweden
  • Designed to deliver comprehensive, full-service bioanalytical and biomarker solutions
  • Supports pharmaceutical and biotechnology customers across all phases of drug development
  • Helps customers globally accelerate innovation and bring new therapies to patients faster

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, located within GoCo Health Innovation City. This new facility expands the company’s global bioanalytical capabilities to support pharmaceutical and biotechnology customers across all phases of drug development.

With state-of-the-art instrumentation and Good Laboratory Practice (GLP) capabilities, the laboratory provides rapid, reliable bioanalytical and biomarker services across the full drug development lifecycle, from preclinical studies through post-approval. Its advanced technology suite includes cell-based assays, immunochemistry, liquid chromatography-mass spectrometry, molecular genomics, flow cytometry and proteomics, supporting both small molecules and complex therapeutic modalities such as peptides, antibodies, oligonucleotides, and cell and gene therapies.

“Our new Gothenburg laboratory is purpose-built to address the evolving needs of modern drug development, particularly as therapies become more complex and data requirements increase,” said Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific. “By investing in advanced capabilities and strategic locations, such as Gothenburg, we are helping our customers in Europe and globally accelerate innovation and bring new therapies to patients faster.”

Thermo Fisher Scientific's PPD™ Laboratory services support clinical trials at all levels and offers integrated support through its network of bioanalytical, biomarker, GMP, vaccine sciences and central labs to enhance clinical trial and drug development efficiency. The new lab in Gothenburg complements the business’ other bioanalytical labs in Richmond, Virginia, and Suzhou, China, and it reinforces the company’s long-term commitment to the Swedish life sciences ecosystem and continued growth as a major employer and investor in the region.

Frequently Asked Questions

What does the new lab add to the life sciences industry?

  • The lab in Gothenburg, Sweden, expands the company’s global bioanalytical capabilities to support global pharmaceutical and biotechnology customers across all phases of drug development.

Who is it designed for?

  • The new lab strengthens support for pharmaceutical and biotechnology customers across all phases of drug development.

What problem does it solve?

  • The facility enhances Thermo Fisher Scientific’s ability to deliver rapid, reliable bioanalytical services from preclinical development through post-approval studies, helping customers accelerate innovation and bring new therapies to patients faster.

Why does it matter?

  • The lab complements Thermo Fisher's existing bioanalytical laboratories in the U.S. and China while reinforcing Thermo Fisher Scientific’s long-term commitment to the Swedish life sciences ecosystem, supporting regional growth, employment, and investment.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Contacts

Media Contact Information:
Nadine Maeser
E-mail: nadine.maeser@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Nadine Maeser
E-mail: nadine.maeser@thermofisher.com

More News From Thermo Fisher

Nalgene Outdoor Expands Mythical Creatures Collection with Mothman, The Loch Ness Monster and Jackalope

ROCHESTER, N.Y.--(BUSINESS WIRE)--Just in time for Halloween, Nalgene Outdoor is adding a little inspiration to spooky season and trick-or-treat traditions with three new designs in its limited-edition Mythical Creatures collection: Mothman, the Loch Ness Monster and Jackalope. The new designs join aliens, werewolves and Sasquatch, bringing six legendary characters to Nalgene’s iconic 32-ounce bottles just in time for fall traditions. Whether they inspire a last-minute Halloween costume, come a...

Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026

MILAN--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, is expanding its drug development, manufacturing, and clinical capabilities to help pharmaceutical and biotechnology companies navigate increasingly complex paths to commercialization, reduce friction, and maintain momentum. The company will showcase these new and expanded capabilities at CPHI Milan 2026, Oct. 6-8. Among the new offerings is OSD Express, a defined solution designed to increase predictability...

Thermo Fisher Scientific Proteomics Technologies Enable Discovery of More Than 2,500 New Biological Associations in PRECISE-SG100K Study

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its strategic collaboration with Precision Health Research, Singapore (PRECISE) and Nanyang Technological University, Singapore (NTU Singapore) has led to the discovery of more than 2,500 previously unreported genetic-protein associations. By combining Thermo Fisher’s complementary proteomics technologies with PRECISE-SG100K's large-scale health and genomic data, researchers...
Back to Newsroom